E
Elisa Cerqui
Researcher at University of Brescia
Publications - 28
Citations - 1680
Elisa Cerqui is an academic researcher from University of Brescia. The author has contributed to research in topics: Transplantation & Azacitidine. The author has an hindex of 12, co-authored 26 publications receiving 1376 citations.
Papers
More filters
Journal ArticleDOI
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
Francesco Lo-Coco,Giuseppe Avvisati,Marco Vignetti,Christian Thiede,Simona Iacobelli,Felicetto Ferrara,Paola Fazi,Laura Cicconi,E. Di Bona,Giorgina Specchia,Simona Sica,Mariadomenica Divona,Alessandro Levis,Walter Fiedler,Elisa Cerqui,Massimo Breccia,Giuseppe Fioritoni,Mario Cazzola,L. Melillo,Enrica Morra,Bernd Hertenstein,Mohammed Wattad,Michael Lübbert,Mathias Hänel,Norbert Schmitz,Alessandro Rambaldi,G. La Nasa,Mario Luppi,Fabio Ciceri,Olimpia Finizio,Adriano Venditti,Francesco Fabbiano,Konstanze Döhner,M. Sauer,Arnold Ganser,Sergio Amadori,Franco Mandelli,Hartmut Döhner,Gerhard Ehninger +38 more
TL;DR: ATRA plus arsenic trioxide is at least not inferior and may be superior to ATRA plus chemotherapy in the treatment of patients with low-to-intermediate-risk APL.
Journal ArticleDOI
Randomized Phase III Trial of Retinoic Acid and Arsenic Trioxide Versus Retinoic Acid and Chemotherapy in Patients With Acute Promyelocytic Leukemia: Health-Related Quality-of-Life Outcomes
Fabio Efficace,Franco Mandelli,Giuseppe Avvisati,Francesco Cottone,Felicetto Ferrara,Eros Di Bona,Giorgina Specchia,Massimo Breccia,Alessandro Levis,Simona Sica,Olimpia Finizio,Maria Grazia Kropp,Giuseppe Fioritoni,Elisa Cerqui,Marco Vignetti,Sergio Amadori,Richard F. Schlenk,Uwe Platzbecker,Francesco Lo-Coco +18 more
TL;DR: Overall, current HRQOL findings further support the use of ATRA plus arsenic trioxide as preferred first-line treatment in patients with low- or intermediate-risk APL.
Journal ArticleDOI
PML–RARα kinetics and impact of FLT3 –ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy
Laura Cicconi,Mariadomenica Divona,Claudia Ciardi,Tiziana Ottone,A Ferrantini,Serena Lavorgna,Valentina Alfonso,Francesca Paoloni,Alfonso Piciocchi,Giuseppe Avvisati,Felicetto Ferrara,E. Di Bona,Francesco Albano,Massimo Breccia,Elisa Cerqui,Marco Sborgia,Mariagrazia Kropp,Armando Santoro,Alessandro Levis,Simona Sica,Sergio Amadori,Maria Teresa Voso,Franco Mandelli,Francesco Lo-Coco +23 more
TL;DR: It is shown at the molecular level that ATRA–ATO exerts at least equal and probably superior antileukaemic efficacy compared with ATRA-CHT in low–intermediaterisk APL and may abrogate the negative prognostic impact of FLT3–ITD.
Journal ArticleDOI
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis.
Francesca Palandri,Giuseppe A. Palumbo,Massimiliano Bonifacio,Mario Tiribelli,Giulia Benevolo,Bruno Martino,Elisabetta Abruzzese,Mariella D'Adda,Nicola Polverelli,Micaela Bergamaschi,Alessia Tieghi,Francesco Cavazzini,Adalberto Ibatici,Monica Crugnola,Costanza Bosi,Roberto Latagliata,Ambra Di Veroli,Luigi Scaffidi,Federico De Marchi,Elisa Cerqui,Barbara Anaclerico,Giovanna De Matteis,Marco Spinsanti,Elena Sabattini,Lucia Catani,Franco Aversa,Francesco Di Raimondo,Umberto Vitolo,Roberto M. Lemoli,Renato Fanin,Francesco Merli,Domenico Russo,Antonio Cuneo,Maria Letizia Bacchi Reggiani,Michele Cavo,Nicola Vianelli,Massimo Breccia +36 more
TL;DR: Increased disease severity, a delay in RUX start and titrated doses <10 mg BID were associated with patients achievinglower response rates, while an early treatment and higher RUX doses may achieve better therapeutic results.
Journal ArticleDOI
Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
Maria Teresa Voso,Giuseppe Leone,Alfonso Piciocchi,Luana Fianchi,Stella Santarone,Anna Candoni,Marianna Criscuolo,Arianna Masciulli,Elisa Cerqui,Alfredo Molteni,Carlo Finelli,Matteo Parma,Antonella Poloni,A. M. Carella,Francesco Spina,Agostino Cortelezzi,Flavia Salvi,Emilio Paolo Alessandrino,Alessandro Rambaldi,Simona Sica +19 more
TL;DR: This study shows that HSCT is feasible in the majority of patients with HR-MDS/AML/CMML-2 after AZA treatment, and shows that AZA prior to HSCT could be a better option than intensive chemotherapy in higher-risk MDS.